Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
Authors:
- Meng-Lin HuangMHMeng-Lin Huang
- Ming-Jenn ChenMCMing-Jenn Chen
- Chien-Yu LuCLChien-Yu Lu
- Chin-Fan ChenCCChin-Fan Chen
- Pei-Chien TsaiPei-Chien Tsai
- Shih-Chang ChuangSCShih-Chang Chuang
- Ming-Feng HouMHMing-Feng Hou
- Shiu-Ru LinSLShiu-Ru Lin
- Jaw-Yuan WangJWJaw-Yuan Wang
- 1 January 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 21 (1) , 18-25
Abstract
The objective of the study is to investigate whether multiple chemotherapeutic agent-related genetic polymorphisms are associated with the clinical outcomes of Taiwanese metastatic colorectal cancers (mCRC) patients treated with the first-line FOLFOX-4 chemotherapy. Consecutive mCRC patients were prospectively enrolled into this study. Peripheral blood samples were used for genotyping of polymorphisms in MTHFR, DPD, GSTP1, MDR1, TYMS, ERCC1, XRCC1, and ERCC2 genes by polymerase chain reaction–restriction fragment length polymorphism technique and DNA sequencing. The primary end point of the study was to investigate the association of each genetic polymorphism with progression-free survival and overall survival (OS). Favorable genotypes from polymorphisms in ERCC1 codon 118C/C [hazard ratio (HR)=0.061, 95% confidence interval (CI): 0.014–0.274, P<0.001] and XRCC1 codon 399G/G (HR=0.306, 95% CI: 0.103–0.905, P=0.032) that are associated with progression-free survival were identified. Furthermore, ERCC1 codon 118C/C (HR=0.065, 95% CI: 0.011–0.377, P=0.002) and XRCC1 codon 399G/G (HR=0.152, 95% CI: 0.041–0.568, P=0.005) were significantly associated with favorable OS. Combining ERCC1 and XRCC1 genetic polymorphisms, patients with both favorable genotypes of ERCC1 codon 118C/C and XRCC1 codon 399G/G were associated with the better OS than those with one or without any favorable genotypes (P<0.001). The genetic polymorphisms of ERCC1 and XRCC1 may be useful in predicting clinical outcome in Taiwanese mCRC patients treated with FOLFOX-4. However, further prospective studies will be needed for the potential clinical implication.Keywords
This publication has 30 references indexed in Scilit:
- Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced ApoptosisThe Journal of Pharmacology and Experimental Therapeutics, 2005
- ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell linesMolecular Cancer, 2005
- Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and MethotrexateJNCI: Journal of the National Cancer Institute, 2004
- Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivityBritish Journal of Cancer, 2004
- Cancer pharmacogeneticsBritish Journal of Cancer, 2004
- Pharmacogenetics in Cancer TreatmentAnnual Review of Medicine, 2003
- Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapyThe Pharmacogenomics Journal, 2001
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1Journal of Biological Chemistry, 1999
- Overexpression of glutathione S-transferase π enhances the adduct formation of cisplatin with glutathione in human cancer cellsFree Radical Research, 1999